Clinical trial
Chemotherapy in Treating Patients With Prostate Cancer
NCT00004045 · Daiichi Sankyo, Industry · Completed
Key facts
| NCT number | NCT00004045 |
|---|---|
| Title | Chemotherapy in Treating Patients With Prostate Cancer |
| Official title | A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Hormone-Refractory Prostate Cancer |
| Lead sponsor | Daiichi Sankyo, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | exatecan mesylate |
| Start date | Jun 1, 1999 |
| Primary completion | Aug 1, 2001 |
| Completion | Aug 1, 2001 |
| First posted | Apr 15, 2004 |
| Last update posted | May 16, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: